Industry Innovations in MSK Health
Saturday, March 28, 2026
12:15pm – 1:30pm
Organized by the ORS Industry Alliance Committee and the ORS Innovation Committee
Following the successful launch at the 2025 Annual Meeting, ORS will again host a lunch-and-learn educational session in 2026 to highlight specific technical advancements introduced to the market within the past two years by the orthopaedic industry. The goal of this session is to showcase the science and technology behind these innovations.
This event is now at capacity.
Speakers and Their Proposals:
Proposal: OsseoFit® Stemless Shoulder System: A Case Study in Translational Biomechanics
Christine Müri is a Manager of Computational Biomechanics Research at Zimmer Biomet, Switzerland, with 20 years of experience in the orthopedic industry, holding a MSc in Human Movement and Sports Science from ETH Zurich and brings extensive expertise in the development of orthopedic devices, biomechanical modelling, computational simulation, morphological analysis and in silico clinical trials to support evidence-based decision-making. She has been one of the lead engineers in the development of the OsseoFit Stemless Shoulder System and contributed to numerous total knee and total shoulder arthroplasty development projects, guiding them through early design development and optimization through verification.
Christine Müri is passionate about translating complex biomechanical insights into impactful orthopedic solutions, and has authored multiple peer‑reviewed publications, presented at international conferences, and hold several patents in the orthopedics field.
Proposal: Biphasic Degradation of Magnesium Alloy Screws by Bilayer Composite Coating: A Clinically Validated Strategy
Dr. Chen Shi is the Founder and CEO of Suzhou InnoTech Medical Technology Co., Ltd. He received his B.Eng. in Polymer Materials and Science from the Department of Chemical Engineering, Tsinghua University (2012), and his Ph.D. in Chemical Engineering from the University of Alberta, Canada (2016). He subsequently conducted postdoctoral research at the University of California, Los Angeles (UCLA) and the National University of Singapore (NUS). Dr. Shi’s research interest focuses on advanced biomaterials and surface treatment and functionalization. To date, he has published more than 50 peer-reviewed papers and been granted more than 40 patents, and has received honors including the Alberta Innovates Technology Futures scholarship. Dr. Shi has led the development and commercialization of medical devices such as bone defect fillers and negative pressure wound dressings, supported by multiple innovation programs. In 2022, he founded InnoTech in Suzhou to advance the R&D and industrialization of bioresorbable magnesium alloys and resorbable orthopedic devices, aiming to deliver a clinically practical solution for fracture fixation—reliable early stability, controlled resorption, and reduced need for hardware removal. Leveraging high-performance Mg alloys and surface engineering technologies, his team successfully developed products including bioresorbable magnesium cannulated screws. This product has completed clinical studies in 2025, and received both the U.S. FDA Breakthrough Device Designation and China’s innovative medical device “Green Channel,” with parallel NMPA, FDA, and CE registrations targeted for 2026.
Proposal: Closing the Function Gap across Total Knee Arthroplasty: Linking Weight-Bearing Kinematics with Intra-operative Measures
Dr. Alex Fuentes is the CTO and Chief Scientific Officer at Emovi Inc., where he has been a driving force since 2009 in advancing functional diagnostics for orthopedic care. He earned his PhD in biomedical science from the University of Montreal and holds a BSc in athletic therapy from Concordia University. Following a postdoctoral fellowship at ÉTS focused on artificial intelligence applied to biomechanics, Dr. Fuentes brings a unique multidisciplinary perspective bridging biomechanics, AI, and clinical practice.
He currently leads multiple R&D initiatives aimed at personalizing orthopedic care and improving patient outcomes, with his work reflected in numerous peer-reviewed publications, international conference presentations, and two patents.
Proposal: A Scalable Functional NMJ Assay for High-Throughput Evaluation of Botulinum Neurotoxins
Greg Luerman is the VP of Research and Partnerships for Curi Bio where he helps lead commercial and scientific strategy. Following his PhD work, Greg earned a Michael J Fox Foundation postdoctoral fellowship within the Pfizer Neuroscience Research Unit. Greg has remained in industry roles moving from bench to scientific management & commercial leadership positions. Curi Bio is focused on providing translational data using 3D human engineered tissue platforms to overcome the limitations of traditional models.
For more information, please contact [email protected].
